Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression

被引：0
|
作者：
Li, Yunfeng [1 ]
Hu, Maitao [1 ]
Li, Lei [2 ]
Liu, Sheng [1 ]
He, Tingting [3 ]
Cheng, Chunyan [3 ]
Xu, Mian [3 ]
Yin, Xinmin [1 ]
机构：
[1] Hunan Normal Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, 61 Jiefang West Rd, Changsha, Peoples R China
[2] Shandong Univ, Dept Hepatobiliary Surg, Shandong Canc Hosp, Shandong Acad Med Sci, Jinan, Shandong, Peoples R China
[3] OrigiMed, Shanghai, Peoples R China
来源：
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY | 2021年 / 45卷 / 01期
关键词：
GUIDELINES; DIAGNOSIS;
D O I：
10.1016/j.clinre.2020.08.004
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
    Zhang, Ze
    Zhang, Wenwen
    Wang, Hongguang
    Hu, Bingyang
    Wang, Zhanbo
    Lu, Shichun
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [2] Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
    Mou, Haibo
    Yu, Lanfang
    Liao, Qin
    Hou, Xuehua
    Wu, Yinfang
    Cui, Qiang
    Yan, Na
    Ma, Ruobing
    Wang, Lingjian
    Yao, Ming
    Wang, Kai
    [J]. BMC CANCER, 2018, 18
  • [3] Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
    Haibo Mou
    Lanfang Yu
    Qin Liao
    Xuehua Hou
    Yinfang Wu
    Qiang Cui
    Na Yan
    Ruobing Ma
    Lingjian Wang
    Ming Yao
    Kai Wang
    [J]. BMC Cancer, 18
  • [4] Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients
    Hu, Jing
    Li, Bixun
    Zou, Bing
    Wang, Senming
    Qiu, Ye
    Yan, Maolin
    Zeng, Zhiming
    Yang, Han
    Guan, Yan
    Zhang, Lei
    Chen, Wei
    Zhang, Yuan
    Mei, Lei
    Dong, Xiaowei
    Yao, Ming
    Wang, Kai
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [5] Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies
    Thomas, Sean D.
    Jeong, Ah-Reum
    Sakowski, Patrick J.
    Sokol, Ethan S.
    Kurzrock, Razelle
    Goodman, Aaron M.
    [J]. BLOOD, 2020, 136
  • [6] PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
    Fontugne, Jacqueline
    Augustin, Jeremy
    Pujals, Anais
    Compagnon, Philippe
    Rousseau, Benoit
    Luciani, Alain
    Tournigand, Christophe
    Cherqui, Daniel
    Azoulay, Daniel
    Pawlotsky, Jean-Michel
    Calderaro, Julien
    [J]. ONCOTARGET, 2017, 8 (15) : 24644 - 24651
  • [7] MR1 in combination with tumor mutational burden and PD-1/PD-L1 expression as a potentially novel clinical predictor for T cell exhaustion and immune checkpoint inhibitor response.
    Farha, Mark
    Jairath, Neil
    El Naqa, Issam
    Spratt, Daniel Eidelberg
    Lawrence, Theodore
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
    Morrison, Carl
    Pabla, Sarabjot
    Conroy, Jeffrey M.
    Nesline, Mary K.
    Glenn, Sean T.
    Dressman, Devin
    Papanicolau-Sengos, Antonios
    Burgher, Blake
    Andreas, Jonathan
    Giamo, Vincent
    Qin, Moachun
    Wang, Yirong
    Lenzo, Felicia L.
    Omilian, Angela
    Bshara, Wiam
    Zibelman, Matthew
    Ghatalia, Pooja
    Dragnev, Konstantin
    Shirai, Keisuke
    Madden, Katherine G.
    Tafe, Laura J.
    Shah, Neel
    Kasuganti, Deepa
    de la Cruz-Merino, Luis
    Araujo, Isabel
    Saenger, Yvonne
    Bogardus, Margaret
    Villalona-Calero, Miguel
    Diaz, Zuanel
    Day, Roger
    Eisenberg, Marcia
    Anderson, Steven M.
    Puzanov, Igor
    Galluzzi, Lorenzo
    Gardner, Mark
    Ernstoff, Marc S.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [9] HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
    Jing, Chu-Yu
    Fu, Yi-Peng
    Yi, Yong
    Zhang, Mei-Xia
    Zheng, Su-Su
    Huang, Jin-Long
    Gan, Wei
    Xu, Xin
    Lin, Jia-Jia
    Zhang, Juan
    Qiu, Shuang-Jian
    Zhang, Bo-Heng
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma
    Mocan, Lavinia Patricia
    Craciun, Rares
    Grapa, Cristiana
    Melincovici, Carmen Stanca
    Rusu, Ioana
    Al Hajjar, Nadim
    Sparchez, Zeno
    Leucuta, Daniel
    Ilies, Maria
    Sparchez, Mihaela
    Mocan, Tudor
    Mihu, Carmen Mihaela
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (04) : 1003 - 1014
12345